- Before
- Works 14–18 reconsiderations a day, each a question of what applied on a past date — rebuilt from PDFs and a shared drive. “The denial quotes today’s policy. The member got the service in August.”
- Now
- Asks once and gets the edition in force on the date of service, the tracked changes since, and every other decision that cited the same section.
One glucose monitor, from denial to overturn
Dolores Whitfield, 68, a Medicare Advantage HMO member on basal insulin, got a continuous glucose monitor on 18 Aug 2026. The claim for $841.20 was denied on 4 Sep. Here is what happens next, screen by screen, in the working solution.
- 01Filed 28 Sep
A payment reconsideration with a section that looks wrong
Renee Okafor · Appeals nurseAPL-26-04417: Karen Whitfield, her daughter and appointed representative, asks the plan to reconsider claim CLM-26-8836104 from Brightwater Medical Supply — a receiver (E2103) and three months of sensors (A4239). The denial notice says the records do not show meter testing four times a day for 60 days, “as required by medical policy MP-DME-031, section 3.6”. The reconsideration is due 27 Nov.
Margin note on the denial: “Wrong edition. §3.6 took effect 1 Sep 2026 (v9). On 18 Aug 2026, v8 was in force and has no §3.6.”
- 02One question
Service, plan type, date of service — and the answer
Renee Okafor · Appeals nurseRenee asks: continuous glucose monitor, Medicare Advantage HMO, 18 Aug 2026. The answer comes back as a policy page: MP-DME-031 v8, in force 1 Jan to 31 Aug 2026, approved by the UM committee on 9 Dec 2025 — five criteria and a supply limit, §3.1 to §3.5 and §3.7, each quoted with section, edition and page, each marked against LCD L33822.
“On 18 Aug 2026, MA HMO members were reviewed against MP-DME-031 v8: 5 criteria and a supply limit, all within Medicare’s rule.”
- 036.8 seconds
How the answer was found, step by step
The agentsThe question reader turned the words into E2103 and A4239, the plan type and the date of service. The version finder read six editions and picked v8. The Medicare rule checker found LCD L33822 governs. The plan-type comparer found the same criteria for every plan type on that date, and the citation checker matched 6 of 6 quotes to v8 word for word, pages 2–3.
- 04On the strip
The edition the denial quoted
Renee Okafor · Appeals nurseUnder the answer runs every edition of MP-DME-031, from v5 in 2023 to the v10 draft, with Medicare’s rule beside it. Renee clicks v9: §3.6, the testing log, appears underlined in green — added in v9, effective 1 Sep 2026, 14 days after the date of service — not in force for this question.
“Beyond Medicare’s rule. LCD L33822 has had no testing-frequency requirement since 18 Jul 2021, and a Medicare Advantage plan may not add one (42 CFR 422.101(b)(6)).”
- 05Back to v8
Back to the date of service, and §3.6 is struck out
Renee Okafor · Appeals nurseShe moves back to v8. The criteria change in place as tracked changes: §3.6 is struck through in red and folds away. On 18 Aug 2026 the criterion did not exist — and for a Medicare Advantage member it would not apply even later.
“Not in force on 18 Aug 2026 — v9 added it 1 Sep 2026.”
- 06Side by side
The same criteria, five plan types
Plan-type comparerThe plan-type comparison lays each criterion across Medicare Advantage HMO and PPO, Medicaid managed care, commercial employer group and individual exchange. Under today’s v9 it shows §3.4(a) narrowed for commercial and exchange to three or more insulin injections a day or a pump — and §3.6 applied to every plan type, Medicare Advantage included.
- 07Redline
What changed between v8 and v9, and who approved it
Change trackerThe full tracked changes: one change, §3.6 inserted by v9, approved by the UM committee on 11 Aug 2026. The edition list shows each edition’s summary and approval, and marks v8 “on the date asked” and v9 “beyond Medicare”.
- 08Run the check
The records against v8, and a drafted overturn
Decision drafterOn the appeal, five steps: read the denial, find the edition in force on 18 Aug 2026, check Medicare’s rule, match the records to v8 §3.1–§3.5, draft the decision. Type 2 diabetes, a prescription and an in-person visit on 2 Jul 2026, insulin glargine 22 units daily — 5 of 5 met, §3.6 not in force. Recommended: overturn, pay $841.20 to Brightwater Medical Supply, with the rationale cited and editable.
“Five steps, about 8 seconds. Nothing is decided by the agents.”
- 09Signed
The physician reviewer decides
Dr. Samuel Achterberg · Physician reviewerRenee sends the case to Dr. Achterberg with the dated answer and five citations. He sees the edition in force, MP-DME-031 v8, the Medicare rule, LCD L33822, and 5 of 5 criteria met — and signs the overturn. Payment of $841.20 is released, and Renee sends the decision letter to Ms. Whitfield and the supplier.
- 10Same citation
Forty other members, found and sent back for review
Renee Okafor · Appeals nurseSince 1 Sep, 41 decisions on Medicare Advantage members cited §3.6: 29 claims with $31,870 denied and 12 prior authorizations. In 9 the service came before 1 Sep, when §3.6 did not exist; 7 are already appealed. Renee sends 40 to re-review and tells the director of medical policy. On 21 Oct the UM committee votes on v10, which limits §3.6 to commercial and exchange plans.